Prostate cancer: Reducing overtreatment: Active surveillance in low-risk disease

Nature Reviews Urology

Volumn 8, Issue 3, 2011, Pages 124-125

  Whitson, Jared M ^a   Porten, Sima P ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE INHIBITOR;

BRACHYTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DISEASE SURVEILLANCE; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SHORT SURVEY; TREATMENT PLANNING; TUMOR VOLUME;

HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 79952705000     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.8     Document Type: Short Survey

References (10)

1. Andriole, G. L. et al. Mortality results from a randomized prostate cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
2. Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
3. Hugosson, J. et al. Mortality results from the Göteborg randomised population-based prostate cancer screening trial. Lancet Oncol. 11, 725-732 (2010).
4. Carroll, P. R., Whitson, J. M. & Cooperberg, M. R. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J. Clin. Oncol. doi:10.1200/JCO.2010.32.5308.
5. Loeb, S. et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J. Clin. Oncol. doi:10.1200/JCO.2010.30.6373.
6. Dall'Era, M. A. et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112, 2664-2670 (2008).
7. Klotz, L. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28, 126-131 (2010).
8. Hayes, J. H. et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304, 2373-2380 (2010).
9. Cooperberg, M. R. et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J. Clin. Oncol. 29, 228-234 (2011).
10. Fleshner, N. et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp. Clin. Trials 28, 763-769 (2007).